NYXH Nyxoah SA

0.8222USD0.7480 EUR · EBR-6.38%Mkt Cap: 83.73M USDP/E: —

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for …

Institutional holders14 on file

Key Statistics

Company
Market Cap83.73M USD
Enterprise Value58.21M USD
Revenue (TTM)31.72M USD
Gross Profit6.95M USD
Net Income (TTM)-99.02M USD
Revenue/Share0.52 USD
Last Price0.8222 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees153
CountryBE
SectorHealthcare
IndustryMedical Devices
ISINBE0974358906
Valuation
P/E (Trailing)—
P/E (Forward)-1.48
PEG—
EV/EBITDA-0.66
EV/Revenue1.83
P/S2.64
P/B1.12
EPS (TTM)-1.77 USD
EPS (Forward)-0.55 USD
52W Range
0.76611% of range5.205
52W High5.205 USD
52W Low0.7661 USD
Profitability
Gross Margin63.13%
Oper. Margin-282.53%
EBITDA Margin-278.09%
Profit Margin-899.05%
ROE-183.36%
ROA-76.04%
ROIC-199.37%
ROCE-119.32%
Growth
Revenue Growth365.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.82M USD
CapEx (TTM)4.14M USD
FCF Margin-159.38%
FCF Yield-60.38%
Net Debt-25.52M USD
Net Debt/EBITDA0.29
Net Debt/FCF—
Balance Sheet
Debt/Equity0.82
Current Ratio2.19
Quick Ratio2.04
Book Value/Sh0.73 USD
Cash/Share0.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.653 USD
Upside (mean)+466.0%
Target Range1.099 USD – 6.705 USD
1.099+466.0% to mean6.705
# Analysts3
Ownership
Shares Out.101.84M
Float52.55M
Insiders33.19%
Institutions25.00%
Technical
SMA 501.144 (-28.2%)
SMA 2002.106 (-61.0%)
Beta1.02
S&P 52W Chg8.68%
Avg Vol (30d)264.38K
Avg Vol (10d)199.87K
Technical Indicators
RSI (14)33.1
MACD-0.0620
MACD Signal-0.0776
MACD Hist.+0.0157
BB Upper0.9286 USD
BB Middle0.8722 USD
BB Lower0.8158 USD
BB Width12.93%
ATR (14)0.0772 USD
Vol Ratio (20d)0.83x

About Nyxoah (EBR: NYXH)

›

Nyxoah (EBR: NYXH) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 153 employees.

The shares were at 0.7480 EUR on 20 November 2026, down 81.6% over 52 weeks. Its 52-week range is 0.6970 EUR to 4.735 EUR: the price is 84.2% below the high and 7.3% above the low.

Its market capitalisation is 76.18M EUR.

Nyxoah reports return on equity of -183.4%, an operating margin of -282.5% and revenue up 365.0% year over year.

It holds more cash than debt, a net cash position of 23.22M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.